- Home
- ADAP vs AVIR Comparison
ADAP vs AVIR Comparison
Compare ADAP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- AVIR
- Stock Information
- Founded
- ADAP 2008
- AVIR 2012
- Country
- ADAP United Kingdom
- AVIR United States
- Employees
- ADAP N/A
- AVIR N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- ADAP Health Care
- AVIR Health Care
- Exchange
- ADAP Nasdaq
- AVIR Nasdaq
- Market Cap
- ADAP 212.3M
- AVIR 247.5M
- IPO Year
- ADAP 2015
- AVIR 2020
- Fundamental
- Price
- ADAP $0.62
- AVIR $3.21
- Analyst Decision
- ADAP Strong Buy
- AVIR Hold
- Analyst Count
- ADAP 4
- AVIR 1
- Target Price
- ADAP $2.79
- AVIR $6.88
- AVG Volume (30 Days)
- ADAP 2.3M
- AVIR 353.3K
- Earning Date
- ADAP 11-13-2024
- AVIR 11-07-2024
- Dividend Yield
- ADAP N/A
- AVIR N/A
- EPS Growth
- ADAP N/A
- AVIR N/A
- EPS
- ADAP N/A
- AVIR N/A
- Revenue
- ADAP $175,041,000.00
- AVIR N/A
- Revenue This Year
- ADAP $204.91
- AVIR N/A
- Revenue Next Year
- ADAP N/A
- AVIR N/A
- P/E Ratio
- ADAP N/A
- AVIR N/A
- Revenue Growth
- ADAP 146.27
- AVIR N/A
- 52 Week Low
- ADAP $0.43
- AVIR $2.75
- 52 Week High
- ADAP $2.05
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- ADAP 37.29
- AVIR 52.25
- Support Level
- ADAP $0.57
- AVIR $3.04
- Resistance Level
- ADAP $0.61
- AVIR $3.24
- Average True Range (ATR)
- ADAP 0.04
- AVIR 0.16
- MACD
- ADAP -0.00
- AVIR 0.01
- Stochastic Oscillator
- ADAP 27.46
- AVIR 62.03
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).